18F-AzaFol for Detection of Folate Receptor-β Positive Macrophages in Experimental Interstitial Lung Disease—A Proof-of-Concept Study

Background: Interstitial lung disease (ILD) is a common and severe complication in rheumatic diseases. Folate receptor-β is expressed on activated, but not resting macrophages which play a key role in dysregulated tissue repair including ILD. We therefore aimed to pre-clinically evaluate the potential of 18F-AzaFol-based PET/CT (positron emission computed tomography/computed tomography) for the specific detection of macrophage-driven pathophysiologic processes in experimental ILD. Methods: The pulmonary expression of folate receptor-β was analyzed in patients with different subtypes of ILD as well as in bleomycin (BLM)-treated mice and respective controls using immunohistochemistry. PET/CT was performed at days 3, 7, and 14 after BLM instillation using the 18F-based folate radiotracer 18F-AzaFol. The specific pulmonary accumulation of the radiotracer was assessed by ex vivo PET/CT scans and quantified by ex vivo biodistribution studies. Results: Folate receptor-β expression was 3- to 4-fold increased in patients with fibrotic ILD, including idiopathic pulmonary fibrosis and connective tissue disease-related ILD, and significantly correlated with the degree of lung remodeling. A similar increase in the expression of folate receptor-β was observed in experimental lung fibrosis, where it also correlated with disease extent. In the mouse model of BLM-induced ILD, pulmonary accumulation of 18F-AzaFol reflected macrophage-related disease development with good correlation of folate receptor-β positivity with radiotracer uptake. In the ex vivo imaging and biodistribution studies, the maximum lung accumulation was observed at day 7 with a mean accumulation of 1.01 ± 0.30% injected activity/lung in BLM-treated vs. control animals (0.31 ± 0.06% % injected activity/lung; p < 0.01). Conclusion: Our preclinical proof-of-concept study demonstrated the potential of 18F-AzaFol as a novel imaging tool for the visualization of macrophage-driven fibrotic lung diseases.

[1]  D. Lynch,et al.  Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. , 2021, Radiology.

[2]  S. Markovic,et al.  Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy , 2020, Journal of experimental & clinical cancer research : CR.

[3]  Ø. Molberg,et al.  Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. , 2019, American journal of respiratory and critical care medicine.

[4]  S. Danoff,et al.  Interstitial Lung Disease in Polymyositis and Dermatomyositis. , 2019, Clinics in chest medicine.

[5]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[6]  Y. Tsushima,et al.  Clinical value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis , 2019, The Journal of dermatology.

[7]  T. Frauenfelder,et al.  Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2 , 2018, Annals of the rheumatic diseases.

[8]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[9]  F. Borgna,et al.  In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs. , 2018, Molecular pharmaceutics.

[10]  S. Goldman,et al.  Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients , 2018, Respiratory Research.

[11]  O. Distler,et al.  Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis , 2018, Arthritis Research & Therapy.

[12]  M. Bajénoff,et al.  Lymph node macrophages: Scavengers, immune sentinels and trophic effectors. , 2018, Cellular immunology.

[13]  S. Ametamey,et al.  Diastereomerically Pure 6R- and 6S-3′-Aza-2′-18F-Fluoro-5-Methyltetrahydrofolates Show Unprecedentedly High Uptake in Folate Receptor–Positive KB Tumors , 2018, The Journal of Nuclear Medicine.

[14]  P. Low,et al.  Aluminum fluoride-18 labeled folate enables in vivo detection of atherosclerotic plaque inflammation by positron emission tomography , 2018, Scientific Reports.

[15]  C. Denton,et al.  Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease , 2018, Rheumatology.

[16]  A. Passeri,et al.  THU0425 18f-fluorodeoxyglucose positron emission tomography/computed tomography and lung involvement in systemic sclerosis , 2018, THURSDAY, 14 JUNE 2018:.

[17]  S. Kubo,et al.  Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts , 2018, Journal of clinical biochemistry and nutrition.

[18]  Patrick Hess,et al.  A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model , 2018, PLoS ONE.

[19]  P. Low,et al.  Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [18F]Fluoro-PEG-Folate , 2018, Contrast media & molecular imaging.

[20]  J. Corander,et al.  Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study , 2018, Rheumatology.

[21]  B. Hutton,et al.  Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  M. Urowitz,et al.  Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. , 2017, Current rheumatology reviews.

[23]  M. Glassberg,et al.  Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts , 2017, Current Rheumatology Reports.

[24]  M. Baron,et al.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) , 2017, Annals of the rheumatic diseases.

[25]  M. Kolb,et al.  Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis , 2017, Scientific Reports.

[26]  M. Kolb,et al.  Therapeutic targets in idiopathic pulmonary fibrosis. , 2017, Respiratory medicine.

[27]  D. Guilloteau,et al.  TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases? , 2017, Contrast media & molecular imaging.

[28]  C. Maier,et al.  Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis , 2017, Annals of the rheumatic diseases.

[29]  Chiara Spadavecchia,et al.  Respiratory Motion Management in PET/CT: Applications and Clinical Usefulness. , 2017, Current radiopharmaceuticals.

[30]  R. Borie,et al.  [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis , 2017, Respiratory Research.

[31]  M. Mino‐Kenudson,et al.  Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models , 2017, Science Translational Medicine.

[32]  Jaclyn N. Taroni,et al.  A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis , 2017, Genome Medicine.

[33]  E. V. van Beek,et al.  Quantification of Lung PET Images: Challenges and Opportunities , 2017, The Journal of Nuclear Medicine.

[34]  Jakub Toczek,et al.  Matrix Metalloproteinase–Targeted Imaging of Lung Inflammation and Remodeling , 2017, The Journal of Nuclear Medicine.

[35]  K. Togashi,et al.  18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease , 2016, The Journal of Nuclear Medicine.

[36]  D. Vummidi,et al.  Management of connective tissue diseases associated interstitial lung disease: a review of the published literature , 2016, Current opinion in rheumatology.

[37]  T. Maher,et al.  Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? , 2016, Trends in molecular medicine.

[38]  D. Dimitrov,et al.  High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity , 2016, Leukemia.

[39]  H. Collard,et al.  Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes , 2016, Scientific Reports.

[40]  S. Rafii,et al.  Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis , 2016, Nature Medicine.

[41]  U. Himmelreich,et al.  Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume , 2016, Disease Models & Mechanisms.

[42]  P. Low,et al.  Prediction of Response to Therapy for Autoimmune/Inflammatory Diseases Using an Activated Macrophage-Targeted Radioimaging Agent. , 2015, Molecular pharmaceutics.

[43]  L. Gregory,et al.  Pulmonary macrophages: key players in the innate defence of the airways , 2015, Thorax.

[44]  D. Lynch,et al.  CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. , 2015, The Lancet. Respiratory medicine.

[45]  H. Binder,et al.  Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis , 2015, PloS one.

[46]  Viktor Martyanov,et al.  Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms , 2015, PLoS Comput. Biol..

[47]  K. Brown,et al.  Interstitial Lung Disease in Undifferentiated Forms of Connective Tissue Disease , 2015, Arthritis care & research.

[48]  G. Van Simaeys,et al.  PET/CT with 18F-FDG– and 18F-FBEM–Labeled Leukocytes for Metabolic Activity and Leukocyte Recruitment Monitoring in a Mouse Model of Pulmonary Fibrosis , 2015, The Journal of Nuclear Medicine.

[49]  P. Low,et al.  Folate Receptor-β Imaging Using 99mTc-Folate to Explore Distribution of Polarized Macrophage Populations in Human Atherosclerotic Plaque , 2014, The Journal of Nuclear Medicine.

[50]  Athol U. Wells,et al.  Interstitial lung disease in connective tissue disease—mechanisms and management , 2014, Nature Reviews Rheumatology.

[51]  L. Gleaves,et al.  Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation. , 2014, American journal of respiratory cell and molecular biology.

[52]  R. Hubbard,et al.  Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. , 2014, Annals of the American Thoracic Society.

[53]  K. Hasui,et al.  Depletion of folate receptor β-expressing macrophages alleviates bleomycin-induced experimental skin fibrosis , 2014, Modern rheumatology.

[54]  A. Spira,et al.  Association of Interferon‐ and Transforming Growth Factor β–Regulated Genes and Macrophage Activation With Systemic Sclerosis–Related Progressive Lung Fibrosis , 2014, Arthritis & rheumatology.

[55]  Kim Van der Heiden,et al.  Folate Receptor–Targeted Single-Photon Emission Computed Tomography/Computed Tomography to Detect Activated Macrophages in Atherosclerosis: Can It Distinguish Vulnerable from Stable Atherosclerotic Plaques? , 2014, Molecular imaging.

[56]  H. Perlman,et al.  Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. , 2013, American journal of respiratory cell and molecular biology.

[57]  J. Renauld,et al.  Lung inflammation and thymic atrophy after bleomycin are controlled by the prostaglandin D2 receptor DP1. , 2013, American journal of respiratory cell and molecular biology.

[58]  F. Bonella,et al.  CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. , 2013, Respiratory medicine.

[59]  B. Hutton,et al.  Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  P. Low,et al.  Direct in vivo evidence of activated macrophages in human osteoarthritis. , 2013, Osteoarthritis and cartilage.

[61]  S. Ametamey,et al.  Radiosynthesis and preclinical evaluation of 3'-Aza-2'-[(18)F]fluorofolic acid: a novel PET radiotracer for folate receptor targeting. , 2013, Bioconjugate chemistry.

[62]  B. Hutton,et al.  18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  Roger N Gunn,et al.  An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  H. Weinans,et al.  Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. , 2011, Arthritis and rheumatism.

[65]  P. Low,et al.  A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity , 2011, Arthritis research & therapy.

[66]  James Lyons-Weiler,et al.  Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. , 2011, Arthritis and rheumatism.

[67]  Robert B. Innis,et al.  Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands , 2011, The Journal of Nuclear Medicine.

[68]  Roger N Gunn,et al.  Two Binding Sites for [3H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[69]  Baohui Xu,et al.  Effect of an immunotoxin to folate receptor β on bleomycin‐induced experimental pulmonary fibrosis , 2010, Clinical and experimental immunology.

[70]  P. Low,et al.  Imaging of Atherosclerosis in Apoliprotein E Knockout Mice: Targeting of a Folate-Conjugated Radiopharmaceutical to Activated Macrophages , 2010, Journal of Nuclear Medicine.

[71]  E. White,et al.  Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[72]  R. Elashoff,et al.  Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. , 2009, Chest.

[73]  P. Low,et al.  Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.

[74]  A. Groves,et al.  Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with 18F-FDG PET/CT , 2009, Journal of Nuclear Medicine.

[75]  A. Alavi,et al.  Functional imaging of inflammatory diseases using nuclear medicine techniques. , 2009, Seminars in nuclear medicine.

[76]  P. Low,et al.  A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. , 2009, Blood.

[77]  G. Laurent,et al.  Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? , 2007, European Respiratory Journal.

[78]  N. D. Di Paolo,et al.  Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells , 2007, Nature.

[79]  D. Nutt,et al.  Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. , 2006, Trends in pharmacological sciences.

[80]  N. Siafakas,et al.  Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. , 2005, Chest.

[81]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[82]  J. Vansteenkiste,et al.  Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. , 2004, Respiratory medicine.

[83]  J. Reddy,et al.  Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[84]  Philip S Low,et al.  Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. , 2004, Advanced drug delivery reviews.

[85]  Neil Smith.  A review of the published literature into cannabis withdrawal symptoms in human users. , 2002, Addiction.

[86]  R. Escorpizo,et al.  Challenges and Opportunities , 1999, Deep Eutectic Solvents for Pretreatment of Lignocellulosic Biomass.

[87]  P. Casellas,et al.  Peripheral benzodiazepine receptor modulation with phagocyte differentiation. , 1993, Biochemical pharmacology.

[88]  Roger Kurlan,et al.  Management of Nausea and Vomiting , 1987, The American journal of hospice care.

[89]  J M Simpson,et al.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale. , 1988, Journal of clinical pathology.

[90]  J. F. Woessner,et al.  Connective tissue development in subcutaneously implanted polyvinyl sponge. I. Biochemical changes during development. , 1961, Archives of biochemistry and biophysics.

[91]  A. Walch,et al.  Molecular similarities and differences from human pulmonary fibrosis and corresponding mouse model: MALDI imaging mass spectrometry in comparative medicine , 2018, Laboratory Investigation.

[92]  S. Dominique,et al.  Interstitial lung disease in primary Sjögren's syndrome. , 2017, Autoimmunity reviews.

[93]  Kim Van der Heiden,et al.  Folate receptor–targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques? , 2014, Molecular imaging.

[94]  A. Groves,et al.  Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease : Implications from Initial Experience with 18 F-FDG PET / CT , 2009 .

[95]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[96]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.

[97]  M. Mann,et al.  Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair , 2015, Molecular systems biology.